Stephen Wren obtained his PhD in Organic Chemistry from Cambridge University. He is highly experienced in medicinal chemistry and has worked on a diverse set of biological targets over many disease areas in several organisations. For examples, he helped to lead the chemistry effort directed towards the identification of SMTC1100 (Summit’s Duchenne Muscular Dystrophy drug), currently undergoing clinical evaluation. Direct experience of CNS research was gained when Stephen guided a team in support of a lead optimisation project for Lundbeck (during his time at Argenta Discovery). In this role, he acted as project leader for the discovery of novel glycine transporter 1 inhibitors for the treatment of schizophrenia. These studies resulted in the identification of a development candidate. Stephen joined Prof. Paul Brennan’s Group at the Oxford Drug Discovery Institute in June 2015 to work on Alzheimer’s drug discovery.